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Background and Purpose—White matter hyperintensities (WMH) of presumed vascular origin increase the risk of stroke 
and dementia. Despite strong WMH heritability, few gene associations have been identified. Relevant experimental 
models may be informative.
Methods—We tested the associations between genes that were differentially expressed in brains of young spontaneously 
hypertensive stroke–prone rats and human WMH (using volume and visual score) in 621 subjects from the Lothian Birth 
Cohort 1936 (LBC1936). We then attempted replication in 9361 subjects from the Cohorts for Heart and Aging Research 
in Genomic Epidemiology (CHARGE). We also tested the subjects from LBC1936 for previous genome-wide WMH 
associations found in subjects from CHARGE.
Results—Of 126 spontaneously hypertensive stroke–prone rat genes, 10 were nominally associated with WMH volume or 
score in subjects from LBC1936, of which 5 (AFP, ALB, GNAI1, RBM8a, and MRPL18) were associated with both WMH 
volume and score (P<0.05); 2 of the 10 (XPNPEP1, P=6.7×10−5; FARP1, P=0.024) plus another spontaneously hypertensive 
stroke–prone rat gene (USMG5, P=0.00014), on chromosomes 10, 13, and 10 respectively, were associated with WMH 
in subjects from CHARGE. Gene set enrichment showed significant associations for downregulated spontaneously 
hypertensive stroke–prone rat genes with WMH in humans. In subjects from LBC1936, we replicated CHARGE’s genome-
wide WMH associations on chromosomes 17 (TRIM65 and TRIM47) and, for the first time, 1 (PMF1).
Conclusions—Despite not passing multiple testing thresholds individually, these genes collectively are relevant to known 
WMH associations, proposed WMH mechanisms, or dementia: associations with Alzheimer's disease, late-life depression, 
ATP production, osmotic regulation, neurodevelopmental abnormalities, and cognitive impairment. If replicated 
further, they suggest a multifactorial nature for WMH and argue for more consideration of vascular contributions to 
dementia.   (Stroke. 2015;46:341-347. DOI: 10.1161/STROKEAHA.114.007649.)
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White matter hyperintensities (WMH) of presumed vas-cular origin, a major component of cerebral small ves-
sel disease (SVD), double the risk of stroke and dementia.1 
Despite considerable societal effect, the causes of WMH and 
SVD are poorly understood.2 Conventional vascular risk fac-
tors explain little of the WMH variance.3 Family studies,4 
several rare monogenic SVD disorders,5 and epidemiology6 
suggest that genetic predisposition is important.
Identification of genetic factors for SVD has been chal-
lenging. Several replicable single-nucleotide polymorphisms 
(SNPs) associated with WMH have been identified in 1 locus 
on chromosome 17q25,7,8 although the exact gene(s) and bio-
logical pathways to WMH are unclear. Few other replicable 
genes have been found in genome-wide association studies 
(GWAS),9,10 and little is known of their functional significance.
Experimental SVD models might provide insight into 
human SVD. The spontaneously hypertensive stroke–prone 
rat (SHRSP) is a relevant model of spontaneous SVD.11 It 
was selectively crossbred (1974) from Wistar-Kyoto (WKY) 
rats via the spontaneously hypertensive rat (SHR, 1963).12 
Hypertension, established in SHRSP rats by 10 weeks of 
age, is considered to be the main cause of their brain disease. 
However, differences in protein and gene expression in SHRSP 
rats versus WKY rats at 5 weeks of age (before measurable 
blood pressure rises) suggest underlying susceptibilities to 
SVD.13 Compared with WKY controls, 5-week-old SHRSP 
rats have reduced claudin 5 (tight junction) and myelin basic 
protein and increased microglia (IBA1) and glial activation 
(GFAP)13; at 16 and 21 weeks, increase in smooth muscle actin 
was seen, thought to reflect arteriolar smooth muscle hyperpla-
sia secondary to hypertension. SHRSP gene expression differ-
ences at 5 weeks of age were more numerous than at 16 or 21 
weeks of age and included downregulation of Mmp14, Mbp, 
GFAP, AVP, Alb, and Igf2, upregulation of Gucy1A3, Rps9, 
Fos, and JunB, early-growth response, cell-signaling genes, 
and overexpression of genes involved in neurological diseases 
(stroke, depression, and blood–brain barrier leakage),14 rather 
than just hypertension. Recent gene sequencing of SHRSP 
rats (and 26 other rat models of common human diseases)15 
revealed that genes that were either shared between or uniquely 
mutated in these rat models were significantly over-represented 
in human GWAS hits for hypertension or metabolism-related 
phenotypes, suggesting coevolution of these genes and their 
role in common diseases in models and humans.15
In a hypothesis-driven collaborative approach, we tested for 
associations between genes that were differentially expressed 
in the brains of 5-week-old SHRSP rats14 and WMH in 
humans. We used data from 5-week-old rats because gene 
expression differences were more frequent at that age than at 
16 or 21 weeks, and we wanted to minimize the confounding 
of tissue changes by secondary effects of hypertension and to 
optimize the chances of detecting genes related to WMH sus-
ceptibility. We focused on WMH as the most frequent feature 
of SVD with the most data available in replication cohorts. 
We first tested the subjects from Lothian Birth Cohort 1936 
(LBC1936)16,17 and then attempted replication in subjects 
from the Cohorts for Heart and Aging Research in Genomic 
Epidemiology (CHARGE) consortium.7 To provide confi-
dence in the relevance of subjects from LBC1936, we also 
sought CHARGE’s7 previously reported WMH-gene associa-
tions in the subjects from LBC1936.
Methods
Subjects
The subjects from LBC1936 are community-dwelling individuals 
living in South East Scotland who underwent detailed cognitive, bio-
medical, genetic assessments, and detailed brain MRI at ≈73 years of 
age (n=866).16,17 The MRI acquisition, methods for assessing WMH 
burden17 qualitatively18 and quantitatively,19 and proportions with 
WMH by either method20 have been reported. This study was ap-
proved by the Lothian (REC 07/MRE00/58) and Scottish Multicentre 
Table 1. Genes Associated With Cerebral Small Vessel Disease in Rats That Are Associated With WMH in Older Humans: 126 
Differentially Expressed Genes Between Spontaneously Hypertensive Stroke Prone and Wild-Type Rats Were Tested for Association 
With WMH in Subjects From LBC1936 and 10 Genes Were Significantly Associated (P<0.05) With Either WMH Volume or Fazekas Score 
Discovery: LBC1936 Replication: CHARGE
Genotyped SNPs Imputed SNPs Imputed SNPs
WMH Volume
Fazekas 
Score WMH Volume
Fazekas 
Score WMH Volume
Chromosome Gene Start Position Stop Position nSNPs P Value P Value nSNPs P Value P Value nSNPs P Value
4 AFP 74 520 796 74 540 356 13 0.0021 0.00090 77 0.0037 0.0037 67 0.841
4 ALB 74 488 869 74 505 834 11 0.0026 0.0017 61 0.0063 0.0068 53 0.718
7 GNAI1 79 602 075 79 686 661 42 0.034 0.033 181 0.014 0.015 166 0.767
1 RBM8A 144 218 994 144 222 801 13 0.038 0.057 26 0.029 0.024 21 0.539
2 INPP5D 233 633 279 233 781 288 69 0.041 0.78 198 0.044 0.87 162 0.989
10 XPNPEP1 111 614 513 111 673 192 18 0.042 0.14 130 0.15 0.23 120 6.7×10–5
9 NR4A3 101 623 957 101 668 994 13 0.045 0.16 62 0.11 0.25 56 0.484
13 FARP1 97 593 434 97 900 024 154 0.049 0.25 550 0.18 0.51 468 0.024
6 MRPL18 160 131 481 160 139 451 24 0.059 0.039 89 0.16 0.048 76 0.224
1 SIPA1L2 230 600 334 230 717 866 80 0.087 0.0093 340 0.20 0.018 285 0.885
nSNPs is the number of SNPs considered in the gene test. CHARGE indicates Cohorts for Heart and Aging Research in Genomic Epidemiology; LBC1936, Lothian Birth 
Cohort 1936; SNP, single-nucleotide polymorphism; and WMH, white matter hyperintensities.
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(MREC/01/0/56) Research Ethics Committees; all subjects gave writ-
ten informed consent.
The subjects from LBC1936 had genome-wide SNP data on 
542 050 SNPs,21 imputed to 2.5 million SNPs with HapMap2.22 There 
were 621 participants (392 men) from LBC1936 with both MRI and 
genetic data (mean age, 72.67 years; SD=0.73 years; Table I and 
Methods in the online-only Data Supplement). We excluded 48 sub-
jects from LBC1936 with a history of stroke or dementia.
Gene Analysis
In the 5-week-old SHRSP rats, 162 genes were differentially ex-
pressed compared with 5-week-old WKY rats in frontal and midcor-
onal brain sections (Table II in the online-only Data Supplement).14 
We used the following databases to match the SHRSP Illumina IDs 
to human genes (Materials and Table II in the online-only Data 
Supplement): Ensembl—http://www.ensembl.org, GeneCards—
http://www.genecards.org, Illumina ID search—http://www.gen-
script.com, NCBI—http://www.ncbi.nlm.nih.gov, and Rat Genome 
Database—http://www.rgd.mcw.edu. Of the 162 SHRSP genes, 132 
had an equivalent human gene, 8 transcripts were mapped to the same 
gene, 20 were uncharacterized in humans, and 2 had no human ho-
mologue. Of the 132 genes, 126 were available for association testing 
using the Versatile Gene-based Association Study (VEGAS) test.23 
We first performed a genome-wide association analysis on subjects 
from LBC1936 using PLINK software24 to test the genetic associa-
tion between 542 050 genotyped SNPs and 2 WMH measurements 
using a linear regression analysis: (1) log transformed WMH volume 
(mL), with age, sex, intracranial volume, and first 4 multiple dimen-
sion scaling components for population stratification as covariates; 
and (2) summed Fazekas score of periventricular and deep WMH, 
with age, sex, and the first 4 multiple dimension scaling population 
stratification components as covariates. We used both WMH volume 
and Fazekas score20 to increase the reliability of the results. We did 
not stratify by vascular risk factors because hypertension (although 
it was the strongest vascular risk factor) explained <2% of WMH 
variance in subjects from LBC1936.3 The VEGAS software summa-
rized evidence for association with WMH in subjects from LBC1936 
per gene by considering the P values of all 543 050 SNPs that were 
located within 17 681 unique autosomal genes (including SNPs±50 
kb outside of genes to include regulatory regions). For a more direct 
comparison with CHARGE (which used imputed data), we also per-
formed a gene-based test on LBC1936’s 2 447 226 HapMap2 derived 
P values (after removing SNPs with a minor allele frequency of <0.01 
and imputation quality of <0.3) with VEGAS software as above.
Replication in Subjects From CHARGE
We then tested whether any of the 126 SHRSP genes were also as-
sociated with WMH in subjects from CHARGE by using data from 
CHARGE’s published genome-wide meta-analysis of WMH in 9361 
stroke-free individuals from 7 community-based cohorts.7 We per-
formed a gene-based test using VEGAS software, which summarized 
the evidence for association with WMH burden on a per gene basis, as 
above, by considering the associated P values of all HapMap2 SNPs 
located within 17 787 autosomal genes (including SNPs±50 kb out-
side of genes to include regulatory regions).
Gene Set Enrichment
We performed a gene set enrichment analysis25 to investigate the en-
richment of the 126 SHRSP genes in the LBC1936 and CHARGE 
data associated with WMH, accounting for whether these were upreg-
ulated or downregulated (online-only Data Supplement),26 corrected 
for multiple testing using a false discovery rate (FDR) method.27
Replication of Previous CHARGE Findings in 
Subjects From LBC1936
To demonstrate our ability to detect WMH-gene associations in 
subjects from LBC1936, we attempted replication of CHARGE’s 
genome-wide associations with WMH7,8 in the subjects from the 
LBC1936 Cohort in a genome-wide association analysis using the 
2 534 887 SNPs imputed to HapMap2, with WMH (volume and 
Fazekas score) in Mach2QTL software.28
We applied Bonferroni correction for multiple testing (P=0.05/126 
genes=0.0004). We did not include the 2 WMH phenotypes in the 
Bonferroni correction as they are highly correlated (r2=0.77). Because 
of the overconservative nature of Bonferroni correction for multiple 
testing,29 a nominal significance threshold of P value of <0.05 was 
required for replication efforts.
Results
SHRSP Genes in Subjects From LBC1936
Of the 126 candidate SHRSP-derived genes, 10 were nominally 
associated with WMH in subjects from LBC1936 (P<0.05; 
Table 1). Using imputed or genotyped data, 5 genes were 
associated with WMH volume (AFP, ALB, GNAI1 [RBM8A 
and INPP5D, both borderline]); 3 of these (AFP, ALB, and 
GNAI1) and 2 others (MRPL18 and SIPA1L2) were associated 
with WMH Fazekas scores. Three other genes were associated 
with WMH volume using genotyped data only (XNXPEP1, 
NR4A3, and FARP1). None of these genes individually passed 
Bonferroni correction in subjects from LBC1936 (all were 
P>0.0004), in part, reflecting the LBC1936 sample size.
SHRSP Genes in Subjects From CHARGE
Two of these 10 genes were also associated with WMH in 
subjects from CHARGE (XPNPEP1, P=6.7×10−5; and 
FARP1, P=0.024; Table 1). Full details of all 126 SHRSP to 
LBC1936 to CHARGE gene associations are given in Table 
III in the online-only Data Supplement. Several other of 
the 126 SHRSP genes (outside the 10/126 described above) 
showed significance at P<0.05 in subjects from CHARGE (eg, 
USMG5, MED17, ZNF461, C20orf7, EGR1, ARC, NUDT14, 
and MMP14) of which 1 (USMG5, P<0.000142) passed 
Bonferroni correction (P<0.0004).
Gene Set Enrichment
Using gene set enrichment analysis, all 126 SHRSP candidate 
genes were not enriched in subjects from LBC1936 for associa-
tion with WMH in the 17 681 genes tested here (WMH volume, 
P=0.34; Fazekas score, P=0.81), but this would not preclude the 
possibility that in either upregulated or downregulated gene sets, 
there was an abundance of genes showing an enriched associa-
tion. We tested the upregulated (n=76) and downregulated (n=50) 
SHRSP genes separately and found significant enrichment 
for Fazekas scores in SHRSP downregulated genes (P=0.035; 
FDR, 0.046) but not SHRSP upregulated genes (P=0.921; FDR, 
0.899). WMH volume showed significant enrichment in down-
regulated (P=0.018; FDR, 0.025) but not upregulated (P=0.802; 
FDR, 0.780) genes. In the CHARGE consortium, there was 
no significant enrichment for either the total set of 126 genes 
(P=0.0514), the upregulated (P=0.109; FDR, 0.266) or the 
downregulated genes (P=0.173; FDR, 0.149).
Replication of CHARGE’s Previous Genome-Wide 
Association in Subjects From LBC1936
We sought CHARGE’s previous genome-wide association 
results for WMH7 in subjects from LBC1936. Of CHARGE’s 
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15 SNPs (P<1×10−5) associated with WMH (Table 2),7 3 SNPs 
replicated in subjects from LBC1936 with both WMH vol-
ume and Fazekas score at P<0.05 (rs3744028, rs1055129, and 
rs1052053); rs1052053, a miss-sense variant on chromosome 
1 in the polyamine-modulated factor 1 gene (PMF1), has not 
replicated previously.
Discussion
We used a clinically relevant translational approach15 to iden-
tify potential new gene associations for WMH, a common 
cause of cognitive impairment, stroke, and dementia. We 
found parallels between differentially expressed genes in a 
young spontaneous SVD model and WMH-gene associations 
in older humans. Two novel genes on chromosome 10 derived 
from SHRSP rats were associated with WMH, XPNPEP1 in 
both LBC1936 and CHARGE and USMG5 in CHARGE only. 
Several other genes were nominally associated with WMH in 
LBC1936 or CHARGE although none passed multiple test-
ing. We replicated 3 of CHARGE’s WMH-gene associations 
in subjects from LBC1936: 2 (rs3744028 and rs1055129) 
on chromosome 17q25 and 1 previously unreplicated SNP 
(rs1052053) on chromosome 1, a miss-sense variant in the 
polyamine-modulated factor 1 gene, PMF1, that has a role 
in the cell cycle. Jointly, these approaches yielded 6 genes (3 
from the SHRSP rats and 3 replicates of a GWAS finding) 
and 5 further rat-derived genes based on the LBC1936 sample 
alone, which despite not passing multiple testing thresholds 
individually, as a group they are notable for their involvement 
in biological pathways relevant to WMH pathogenesis.2
Of the 2 SHRSP genes found in LBC1936 and CHARGE, 
XPNPEP1 is X-prolyl aminopeptidase (aminopeptidase P) 1, 
soluble, associated with biliary atresia, and located in a region 
on chromosome 10 that is associated with Alzheimer's dis-
ease.30 FARP1 is Pleckstrin domain protein 1, associated with 
brain volume differences,31 and important in synapse devel-
opment.32 The SHRSP-CHARGE–associated gene USMG5 is 
upregulated during skeletal muscle growth 5 homolog (also 
known as diabetes mellitus–associated protein in insulin sensi-
tive tissues, or DAPIT), sits on chromosome 10, and maintains 
ATP synthase populations in mitochondria.33 All 5 SHRSP 
genes associated with both WMH volume and Fazekas score 
in subjects from LBC1936 (AFP, ALB, GNAI1, RBM8A, and 
MRPL18) are associated with white matter–relevant diseases 
in humans. Despite not surviving correction for multiple test-
ing, there was a notable consistency in their association with 2 
separate WMH measures. AFP encodes α-fetoprotein, a major 
plasma protein produced in the yolk sac and liver during fetal 
life. Abnormally, high amounts of α-fetoprotein are found in 
ataxia telangiectasia,34 also associated with abnormal white 
matter.35 ALB encodes albumin, a soluble monomeric pro-
tein important for maintaining plasma oncotic pressure found 
in cerebral WMH,36 and cerebrospinal fluid as blood–brain 
barrier function deteriorates with ageing and dementia.2,37 
GNAI1 encodes guanine nucleotide–binding protein (G pro-
tein), alpha-inhibiting activity polypeptide 1, implicated with 
Alzheimer's disease.38 RBM8A is an RNA binding protein that 
has differential expression in Alzheimer's disease,39 associa-
tions with a range of intellectual disabilities in humans and 
anxiety-related behavior in mice,40 with schizophrenia, several 
neurodevelopmental intellectual disabilities, anxiety behavior 
and may target neuronal genes to regulate behaviors. WMH in 
old age are known associates of late-onset depression,41 and 
they are also associated with lower age 11 IQ.42 MRPL18 is the 
mitochondrial ribosomal protein L18, previously associated 
Table 2. Association of SNPs Previously Associated With WMH in CHARGE in Subjects From LBC1936 and the Corresponding SNP 
Association Results Are Given for LBC1936 WMH Volume and Fazekas Score
CHARGE LBC1936 WMH Volume Fazekas Score
SNP Chromosome Nearest Gene Risk Allele Allele Freq P Value
Effect 
Allele Allele Freq r2 β P Value β P Value
rs3744028 17 TRIM65 C 0.18 4.0×10−9 T 0.81 0.99 −0.217 0.00287 −0.287 0.000511
rs1055129 17 TRIM47 G 0.30 4.1×10−8 G 0.28 0.97 0.286 9.5×10−6 0.305 3.34×10−5
rs7894407 10 PDCD11 T 0.63 6.1×10−7 T 0.63 0.99 −0.026 0.662 −0.029 0.665
rs1892525 1 RP11-518D3.1 G 0.69 7.2×10−7 G 0.73 0.99 0.070 0.269 0.107 0.135
rs10814323 9 RECK A 0.21 1.7×10−6 G 0.77 1.00 0.056 0.390 0.034 0.651
rs6992136 8 RPL32P19 G 0.85 3.2×10−6 G 0.85 0.81 0.101 0.259 0.075 0.458
rs11731436 4 AC097110.1 C 0.64 3.3×10−6 G 0.35 0.91 −0.035 0.565 −0.041 0.549
rs1052053 1 PMF1 A 0.62 5×10−6 G 0.39 1.00 −0.112 0.047 −0.127 0.048
rs2167089 3 AC098970.2 G 0.73 6×10−6 T 0.26 0.97 0.061 0.342 0.044 0.545
rs10012573 4 COL25A1 A 0.94 6×10−6 C 0.06 0.85 0.097 0.481 0.029 0.855
rs11625623 14 PTGDR G 0.23 7.7×10−6 G 0.23 1.00 −0.051 0.460 −0.021 0.792
rs16901064 5 RNASEN C 0.84 7.8×10−6 C 0.85 0.99 0.030 0.695 0.055 0.532
rs6945846 7 FOXP2 C 0.2 7.9×10−6 T 0.78 0.90 −0.036 0.625 0.113 0.175
rs11629135 14 MTHFD1 G 0.93 8.6×10−6 G 0.92 0.99 0.034 0.749 −0.057 0.641
rs9410016 9 C9orf62 G 0.41 9.7×10−6 G 0.39 0.99 −0.029 0.603 −0.041 0.521
Allele frequency is the frequency of the effect allele. r 2 is a measure of the imputation quality to HapMap2. β is the regression coefficient. CHARGE indicates 
Cohorts for Heart and Aging Research in Genomic Epidemiology; LBC1936, Lothian Birth Cohort 1936; SNP, single-nucleotide polymorphism; and WMH, white matter 
hyperintensities.
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with multiple sclerosis.43 These 7 SHRSP-derived genes are 
related to pathologies (ataxia telangiectasia, blood–brain 
barrier impairment, Alzheimer's disease, multiple sclerosis, 
depression, developmental intellectual disabilities, and brain 
size) that display white matter abnormalities or affect intellec-
tual function. Impaired ATP production because of defects in 
USMG5, the gene that replicated from SHRSP to CHARGE, 
could increase susceptibility to WMH via ischemia.
The genes that were downregulated in the SHRSP were 
significantly enriched in subjects from LBC1936 for WMH. 
This may be because, in a complex disease such as SVD/
WMH, several individually modest genetic defects in different 
components of key pathways, when present in combination, 
increase disease risk. This interpretation is consistent with dif-
ferential protein expression seen in SHRSP13 and the absence, 
so far, of individual major human gene defects explaining 
either sporadic WMH or lacunar stroke.9
The lack of consistent replication from SHRSP to LBC1936 
to CHARGE requires caution. The power and required sig-
nificance threshold of the LBC1936 was modest for GWAS, 
hence our hypothesis-driven approach. Genes associated with 
WMH in subjects from LBC1936 but not CHARGE could 
be false positives; other factors include greater heterogene-
ity of WMH assessment and greater age range in subjects 
from CHARGE. The narrow age range of subjects from 
LBC1936 minimizes the effect of age, possibly helping to 
expose relevant genes. CHARGE-contributing studies used 
several methods of quantifying WMH, different MR scanner 
field strengths, and generations of technology and sequences. 
However, WMH volume and visual scores are highly cor-
related,20 and our replication of 3 findings from CHARGE 
in subjects from LBC1936 suggests that our approach has 
some validity. The CHARGE cohorts may have used dif-
ferent imputation platforms or more SNPS may have failed 
quality assurance in subjects from LBC1936, contributing to 
differences between the imputation results. There are several 
limitations to gene-based analysis, including the omission of 
nonautosomal genes, the effect of noncausal SNPs to dilute 
association (in particular, in the presence of a strong genetic 
association with a single locus within or in the regulatory 
region of a given gene, thus missing important associations), 
the lack of knowledge on (and overlap of) gene boundar-
ies, the possibility that an SNP variant may influence a gene 
distal to its site, thus not corresponding to a gene that it is 
located next to it, and the potential of the genetic data not to 
tag causative genetic variants. Power may have been limited 
(despite CHARGE’s large sample size) to detect associations 
with some genes. We did not stratify the human cohorts by 
risk factors as these explained <2% of WMH variance in sub-
jects from LBC1936,3 and risk-stratified genetic data were 
unavailable for CHARGE. We did not test gene associations 
with other SVD features in addition to WMH because a total 
SVD burden score was not available for CHARGE. Although 
it is a relevant model of spontaneous SVD11,12 and of human 
hypertension and metabolic disorders,15 like any model, the 
SHRSP has translational limitations, arguing for additional 
studies at different ages and brain regions, with or without 
environmental stressors.
This work has the following strengths: accurate LBC1936 
WMH phenotyping17 and genetic information in this relatively 
large narrow age-range older population.16 The Glasgow SHRSP 
colony is long established, with carefully controlled environ-
ments. The mRNA data were obtained from the same rats that 
provided protein expression data.13 Replication in other SHRSP 
colonies and examination of related strains (eg, SHR’s) may 
be informative. The genomes of SHRSP and 26 other complex 
disease phenotype models were recently sequenced,15 showing 
associations between genes in rat models of hypertension and 
human GWAS hits for hypertension phenotypes.15 This pro-
vides support for our reverse-translational discovery approach, 
suggesting that genes in disease models have coevolved and 
may contribute to disease-related phenotypes in humans.
Our findings require validation. The selection of candidate 
genes for investigation could be widened by examining more 
genes from the 5-week-old SHRSP rats (Table II in the online-
only Data Supplement), other models,15 and in larger samples 
of well-phenotyped humans, such as from METASTROKE 
and the Wellcome Trust Case-Control Consortium. This trans-
lational analysis of experimental models and human disease 
suggests some aspects of the genetic architecture underlying 
SVD, stroke, and dementia and argues for greater awareness 
of vascular contributions to neurodegeneration.
Figure I and Tables IV and V in the online-only Data 
Supplement provide the top SNP (P<1×10−5) and gene 
(P<0.001) associations with WMH variables in subjects from 
LBC1936 for further reference.
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Table I: Description of LBC1936 white matter hyperintensity (WMH) variables. 
Table II: Candidate genes from SHRSP rat model. This is a list of the 162 transcripts 
differentially expressed between SHRSP and WKY at 5 weeks in two relevant brain 
regions, and the corresponding human genes where available.  
 
Table III: Candidate gene-based association results with white matter hyperintensity 
variables (WMH) in the discovery cohort, LBC1936, and the replication cohort, 
CHARGE.  
Table IV: 5 Top hits from genome wide association study with WMH variables in 
LBC1936 (P < 1x10-5). 
Table V: Top gene-based results from LBC1936 for the WMH variables run in Vegas.  
Figure I: Genome-wide association study results of WMH (a) and Fazekas score (b) on 
542,050 SNPs. QQ and Manhattan plots are shown. 
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Supplementary Methods 
Genotyping 
A detailed description of the genotyping method is described elsewhere.1 Briefly, 
genotyping was performed using Illumina Human 610-Quadv1 arrays on blood-extracted 
DNA at the WTCRF Genetics Core. All individuals were checked for disagreement 
between genetic and reported gender. Relatedness between subjects was investigated and, 
for any related pair of individuals, one was removed. Samples with a call rate ≤ 0.95, and 
those showing evidence of non-Caucasian ascent by multidimensional scaling (MDS), 
were also removed. SNPs were included in the analyses if they met the following 
conditions: call rate ≥ 0.98, minor allele frequency ≥ 0.01, and Hardy-Weinberg 
Equilibrium test with P ≥ 0.001. The final number of genotyped SNPs included in the 
study was 542,050 in 1,005 individuals.  
 
Genetic imputation 
~2.5M common SNPs included in HapMap, using the HapMap phase II CEU data as the 
reference sample were imputed. NCBI build 36 (UCSC hg18) was used and genotype 
data were imputed using MACH software. Prior to imputation SNPs were removed that 
diverged from HWE with a significance p <1x10-3 and SNPs with a minor allele 
frequency < 0.01.   
 
Gene mapping.  
Listed below are the databases used to match the Illumina IDs from the SHRSP study to 
human genes as shown in Supplementary Table II. 
Ensembl – www.ensembl.org., GeneCards – www.genecards.org, Illumina ID search - 
www.genscript.com, NCBI - http://www.ncbi.nlm.nih.gov, Rat Genome Database - 
rgd.mcw.edu. 
Gene set enrichment analysis 
A gene set enrichment analysis was performed to investigate the enrichment of 126 
SHRSP genes in WMH gene associations. First, the gene based statistics from VEGAS 
were rank ordered before being –log(10) transformed.  Gene set enrichment analysis 
(GSEA) uses a set of candidate gene identifiers and a genome wide set of genes, ranked 
based on their association with a phenotype. Next, a weighted Kolmogorov-Smirnov type 
statistic, walks down the genome wide ranked set of genes and increases the test statistic 
each time it finds a gene that matches one from the candidate gene set and decreases it 
when it does not.2, 3 The magnitude of the increase is proportional to its p value, allowing 
for information regarding rank and distance between ranks to be used in the calculation of 
enrichment. The maximum deviation from zero is assigned to the candidate gene set (this 
is the enrichment score or ES). The gene set is then permuted before the ES being re-
calculated. The p-value describes the proportion of the 5,000 permuted enrichment scores 
that the observed enrichment score was greater than.  
3 
 
 Table I: Description of LBC1936 WMH variables. Fazekas scale for periventricular 
lesions, Fazekas scale for deep lesions and the sum of these Fazeskas scores are 
described. WMH as percentage of true WMH alone in intracranial volume (ICV) are 
listed.  
Trait Median Mean Standard 
deviation 
Minimum Maximum 
Age in years 72.72 72.67 0.73 71.04 74.22 
Fazekas Peri 1 1.34 0.635 0 3 
Fazekas Deep 1 1.08 0.655 0 3 
Fazekas Sum 2 2.42 1.12 0 6 
ICV mm3 1,448,490 1,452,235.57 141,870.37 1,059,966 1,876,420 
WMH volume 
mm3 
7,554 11,885.97 12,826.30 0 98,378 
WMH 
transformed 
2.1464 2.1135 0.9920 0 4.60 
WMH in ICV 0.5245 0.8203 0.8999 0 7.47 
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Table II: Candidate genes from SHRSP rat model. This is a list of the 162 transcripts differentially expressed between SHRSP and WKY at 5 weeks in two relevant 
brain regions from Bailey et al4 and the corresponding human genes. 
**SHRSP versus WKY differential gene expression at five weeks of age.    *** Human equivalent of SHRSP differentially expressed genes  
              
PROBE_ID ILMN_GENE 
CHROM-
OSOME 
WKY vs SHRSP 
frontal (FDR) 
WKY vs SHRSP 
mid-coronal 
(FDR) 
Rat Gene 
Symbol 
Human 
Gene 
Human Gene Symbol, Human Gene Description Notes 
ILMN_1365113 RGD1564649_PREDICTED   0 0 
Rps9  RPS9 
RPS9    Homo sapiens ribosomal protein S9 (RPS9), mRNA. 
similar to 40S ribosomal 
protein S9 (Pseudo gene) 
ILMN_2038795 RPS9 1 0 0 Rps9  RPS9 As above  
ILMN_1371357 LOC497757   0 0 
Gucy1a3  GUCY1A3 
GUCY1A3 Homo sapiens guanylate cyclase 1, soluble, alpha 3 
(GUCY1A3), transcript variant 1, mRNA. 
 
ILMN_2038796 RPS9 1 0 0 Rps9  RPS9 As above  
ILMN_1359040 RGD1561110_PREDICTED 2 0 0 
Fam151b  FAM151B 
FAM151B Homo sapiens family with sequence similarity 151, member 
B (FAM151B), mRNA. 
 
ILMN_1368735 RGD1311103_PREDICTED   0 0 
 OOEP 
OOEP    Homo sapiens oocyte expressed protein homolog (dog) 
(OOEP), mRNA. 
OOEP is an ortholog 
ILMN_2039673 ARC 7 0 0 
Arc  ARC 
ARC     Homo sapiens activity-regulated cytoskeleton-associated 
protein (ARC), mRNA. 
 
ILMN_1361865 ZFP597 10 0 0 Zfp597  ZNF597 ZNF597  Homo sapiens zinc finger protein 597 (ZNF597), mRNA.  
ILMN_1372230 RNF149 9 4.13E-05 0 Rnf149  RNF149 RNF149  Homo sapiens ring finger protein 149 (RNF149), mRNA.  
ILMN_1350784 JUNB 19 0.00010101 0.00030303 Junb  JUNB JUNB    Homo sapiens jun B proto-oncogene (JUNB), mRNA.  
ILMN_1351340 LOC500950   7.27E-05 0.000187166 
Zfp317  
ZNF317 
ZNF317  Homo sapiens zinc finger protein 317 (ZNF317), transcript 
variant 1, mRNA. 
similar to zinc finger 
protein 75 
ILMN_1368356 FOS 6 0.000117302 0.00030303 
Fos  FOS 
FOS     Homo sapiens FBJ murine osteosarcoma viral oncogene 
homolog (FOS), mRNA. 
 
ILMN_1367486 DUSP1 10 0.00010101 0 Dusp1  DUSP1 DUSP1   Homo sapiens dual specificity phosphatase 1 (DUSP1), mRNA.  
ILMN_1371004 RPS16   0.000117302 0 Rps16  RPS16 RPS16   Homo sapiens ribosomal protein S16 (RPS16), mRNA.  
ILMN_1367530 LOC497727   0.000160428 0.000146628 
Sipa1l2  SIPA1L2 
SIPA1L2 Homo sapiens signal-induced proliferation-associated 1 like 2 
(SIPA1L2), mRNA. 
hypothetical protein 
XP_579313  
ILMN_1372711 LOC502316   0.000160428 0.000146628 
Zfp566  ZNF566 
ZNF566  Homo sapiens zinc finger protein 566 (ZNF566), transcript 
variant 1, mRNA. 
similar to Zinc finger 
protein 566  
ILMN_1367467 PER2 9 0.000383838 0.000465632 Per2  PER2 PER2    Homo sapiens period homolog 2 (Drosophila) (PER2), mRNA.  
ILMN_1367162 GPM6A 16 0.000317125 0.000386364 
Gpm6a  
GPM6A 
GPM6A   Homo sapiens glycoprotein M6A (GPM6A), transcript variant 
1, mRNA. 
 
ILMN_1352667 NAB1   0.000317125 0.000890538 
Nab1  
NAB1 
NAB1    Homo sapiens NGFI-A binding protein 1 (EGR1 binding protein 
1) (NAB1), mRNA. 
 
ILMN_1366713 ZNF575_PREDICTED   0.000227273 0.001603306 Zfp575  ZNF575 ZNF575  Homo sapiens zinc finger protein 575 (ZNF575), mRNA.  
ILMN_1353766 RGD1566136_PREDICTED                 X 0.000317125 8.26E-05 
Rps9  RPS9 
As above 
similar to 40S ribosomal 
protein S9 
ILMN_1353839 PER1   0.000317125 0.00030303 Per1  PER1 PER1    Homo sapiens period homolog 1 (Drosophila) (PER1), mRNA.  
ILMN_1360786 FKBP8 16 0.000317125 0.000125392 Fkbp8  FKBP8 FKBP8   Homo sapiens FK506 binding protein 8, 38kDa (FKBP8), mRNA.  
ILMN_1363342 SLC1A3 2 0.000618182 0.001018182 
Slc1a3  
SLC1A3 
SLC1A3  Homo sapiens solute carrier family 1 (glial high affinity 
glutamate transporter), member 3 (SLC1A3), transcript variant 1, 
mRNA. 
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ILMN_1359704 LOC307332   0.000371901 0.00161442 
Rnf149  RNF149 
As above 
similar to goliath-related 
E3 ubiquitin ligase 4  
ILMN_1364120 POLL 1 0.000714286 0.000847107 
Poll  
POLL 
POLL    Homo sapiens polymerase (DNA directed), lambda (POLL), 
transcript variant 1, mRNA. 
 
ILMN_1362834 DUSP6 7 0.001124807 0.01020475 
Dusp6  
DUSP6 
DUSP6   Homo sapiens dual specificity phosphatase 6 (DUSP6), 
transcript variant 1, mRNA. 
 
ILMN_1369573 LOC688712 19 0.001792208 0.006753247 
Rpl22  
RPL22 RPL22   Homo sapiens ribosomal protein L22 (RPL22), mRNA. 
similar to ribosomal 
protein L22 like 1 
ILMN_1375922 NR4A3 5 0.000482375 0.007217069 
Nr4a3  
NR4A3 
NR4A3   Homo sapiens nuclear receptor subfamily 4, group A, member 
3 (NR4A3), transcript variant 1, mRNA. 
 
ILMN_1349793 LOC684139   0.000651801 0.002306649 
 ZNF582 
ZNF582  Homo sapiens zinc finger protein 582 (ZNF582), mRNA. 
similar to zinc finger 
protein 582 
ILMN_1358205 RGD1560975_PREDICTED   0.008009404 0.028941878 
Tuba1b  TUBA1B 
TUBA1B  Homo sapiens tubulin, alpha 1b (TUBA1B), mRNA. 
similar to Tubulin alpha-2 
chain 
ILMN_1360210 LOC499068   0.001805378 0.01180303 
Zfp583  
ZNF583 
ZNF583  Homo sapiens zinc finger protein 583 (ZNF583), transcript 
variant 1, mRNA. 
similar to Zfp583 protein 
ILMN_1376530 RT1-A3 20 0.000861244 0  HLA-B HLA-B (major histocompatibility complex, class I, B) RT1-A1 is  HLA-B 
ILMN_1369562 LOC499096   0.00119697 0.007554545 
 
ZNF45 ZNF45   Homo sapiens zinc finger protein 45 (ZNF45), mRNA. 
similar to Zinc finger 
protein 45 
ILMN_1368305 LOC499613   0.001124807 0.000277778 
Uncharacteri
sed 
Uncharact
erised 
Uncharacterised 
 
ILMN_1373217 ADPGK   0.001633729 0.000847107 
Adpgk  
ADPGK 
ADPGK   Homo sapiens ADP-dependent glucokinase (ADPGK), 
transcript variant 1, mRNA. 
 
ILMN_1355124 GALNT2_PREDICTED   0.000714286 0.008354978 
Galnt2  
GALNT2 
GALNT2  Homo sapiens UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-acetylgalactosaminyltransferase 2 
(GalNAc-T2) (GALNT2), mRNA. 
 
ILMN_1368809 BTG2 13 0.01057352 0.013769231 Btg2  BTG2 BTG2    Homo sapiens BTG family, member 2 (BTG2), mRNA.  
ILMN_1364113 CTGF 1 0.002249417 0.004427391 Ctgf  CTGF CTGF    Homo sapiens connective tissue growth factor (CTGF), mRNA.  
ILMN_1367428 ZFP189_PREDICTED   0.004554637 0.013664773 
Zfp189  
ZNF189 
ZNF189     Homo sapiens zinc finger protein 189 (ZNF189), transcript 
variant 1, mRNA.  
ILMN_1370045 TRAPPC2                 X 0.002683983 0.008354978 
Trappc2  
TRAPPC2 
TRAPPC2 Homo sapiens trafficking protein particle complex 2 
(TRAPPC2), transcript variant 1, mRNA. 
 
ILMN_1364821 LOC500720   0.009307057 0.028941878 
Uncharacteri
sed 
Uncharact
erised 
Uncharacterised 
 
ILMN_1350533 RGD1563551_PREDICTED 4 0.017192118 0.00161442 
Rpl31  RPL31 
RPL31   Homo sapiens ribosomal protein L31 (RPL31), transcript variant 
1, mRNA. 
 
ILMN_1367827 LOC298998   0.003996212 0.005117845 
Uncharacteri
sed 
Uncharact
erised 
Uncharacterised 
 
ILMN_1352722 LOC316550   0.003839458 0.025268474 
Rab18  RAB18 
RAB18   Homo sapiens RAB18, member RAS oncogene family (RAB18), 
transcript variant 1, mRNA. similar to Rab18 
ILMN_1349422 PTGS2 13 0.004818182 0.016441558 
Ptgs2  
PTGS2 
PTGS2   Homo sapiens prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and cyclooxygenase) (PTGS2), mRNA. 
 
ILMN_1359441 PLA2G2A 5 0.009950187 0.024345238 
Pla2g2a  
PLA2G2A 
PLA2G2A Homo sapiens phospholipase A2, group IIA (platelets, 
synovial fluid) (PLA2G2A), transcript variant 1, mRNA. 
 
ILMN_1357461 ZFP61 1 0.003237998 0.002540107 
No Human 
Homologue 
No 
Human 
Homologu
e 
No Human Homologue  
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ILMN_1368780 CLIC2 20 0.004415584 0.000847107 Clic2  CLIC2 CLIC2   Homo sapiens chloride intracellular channel 2 (CLIC2), mRNA.  
ILMN_1359630 LOC679663 
16|NW_0
47479.1 
0.008343109 0.045305577 
Tceb1  
TCEB1  
TCEB1   Homo sapiens transcription elongation factor B (SIII), 
polypeptide 1 (15kDa, elongin C) (TCEB1), transcript variant 1, mRNA. 
similar to transcription 
elongation factor B (SIII), 
polypeptide 1 
ILMN_1372466 ZCCHC9 2 0.008783107 0.001607143 
Zcchc9  
ZCCHC9 
ZCCHC9  Homo sapiens zinc finger, CCHC domain containing 9 
(ZCCHC9), transcript variant 1, mRNA. 
 
ILMN_1353304 RGD1561287_PREDICTED   0.009307057 0.004159402 
Fam32a  
FAM32A  
FAM32A  Homo sapiens family with sequence similarity 32, member A 
(FAM32A), mRNA. 
family with sequence 
similarity 32, member A 
ILMN_1374612 TM9SF4_PREDICTED   0.01004329 0.023941242 
Tm9sf4  
TM9SF4 
TM9SF4  Homo sapiens transmembrane 9 superfamily protein member 
4 (TM9SF4), mRNA. 
 
ILMN_1368506 LOC497770   0.012253444 0.021175449 
Scn3a  
SCN3A 
SCN3A   Homo sapiens sodium channel, voltage-gated, type III, alpha 
subunit (SCN3A), transcript variant 1, mRNA. 
hypothetical protein 
XP_579373 , - change gene 
name 
ILMN_1362561 LOC498378   0.023521336 0.029085968 
Uncharacteri
sed 
Uncharact
erised 
Uncharacterised 
 
ILMN_1359795 LOC499555   0.009918495 0.024214876 
Uncharacteri
sed 
Uncharact
erised 
Uncharacterised 
 
ILMN_1356628 NFKBIA 6 0.01039312 0.046209617 
Nfkbia  
NFKBIA 
NFKBIA  Homo sapiens nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha (NFKBIA), mRNA. 
 
ILMN_1374199 GIOT1 7 0.006464646 0.013769231  ZNF461 ZNF461  Homo sapiens zinc finger protein 461 (ZNF461), mRNA. GIOT1 is  ZNF461 
ILMN_1353935 FARP1_PREDICTED   0.009307057 0.027335423 
Farp1  
FARP1 
FARP1   Homo sapiens FERM, RhoGEF (ARHGEF) and pleckstrin domain 
protein 1 (chondrocyte-derived) (FARP1), transcript variant 1, mRNA. 
 
ILMN_1362409 BAI2_PREDICTED 5 0.008701299 0.002714097 
Bai2  
BAI2 
BAI2    Homo sapiens brain-specific angiogenesis inhibitor 2 (BAI2), 
mRNA. 
 
ILMN_1370369 EGR2 20 0.009307057 0.003713188 
Egr2  
EGR2 
EGR2    Homo sapiens early growth response 2 (EGR2), transcript 
variant 1, mRNA. 
 
ILMN_1372919 CYR61 2 0.003996212 0.006986166 
Cyr61  
CYR61 
CYR61   Homo sapiens cysteine-rich, angiogenic inducer, 61 (CYR61), 
mRNA. 
 
ILMN_1355401 RGD1563543_PREDICTED   0.021554002 0.0188 Rpl31  RPL31 As above  
ILMN_1362451 RGS2 13 0.007420147 0.0072147 
Rgs2  
RGS2 
RGS2    Homo sapiens regulator of G-protein signaling 2, 24kDa (RGS2), 
mRNA. 
 
ILMN_1365095 DHX40 10 0.011252914 0.030909091 
Dhx40  
DHX40 
DHX40   Homo sapiens DEAH (Asp-Glu-Ala-His) box polypeptide 40 
(DHX40), transcript variant 1, mRNA. 
 
ILMN_1376434 PGRMC1                 X 0.008343109 0.033276328 
Pgrmc1  
PGRMC1 
PGRMC1  Homo sapiens progesterone receptor membrane component 
1 (PGRMC1), mRNA. 
 
ILMN_1349269 SGK 1 0.011998871 0.002164502 
Sgk1  
SGK1 
SGK1    Homo sapiens serum/glucocorticoid regulated kinase 1 (SGK1), 
transcript variant 1, mRNA. 
 
ILMN_1361423 RKHD2_PREDICTED   0.011998871 0.036649595 Mex3c  MEX3C MEX3C   Homo sapiens mex-3 homolog C (C. elegans) (MEX3C), mRNA. RKDHD2 is MEX3C 
ILMN_1649981 STRN3 6 0.01487781 0.042800325 
Strn3  
STRN3 
STRN3   Homo sapiens striatin, calmodulin binding protein 3 (STRN3), 
transcript variant 1, mRNA. 
 
ILMN_1361139 TMPRSS8 10 0.015932282 0.033140909 
Prss30  
PRSS30P 
PRSS30P   Homo sapiens protease, serine, 30 homolog (mouse), 
pseudogene (PRSS30P), non-coding RNA TMPRSS8 is PRSS30P 
ILMN_1357368 LOC497841   0.03056229 0.030909091 
Uncharacteri
sed 
Uncharact
erised 
Uncharacterised 
 
ILMN_1356949 COL6A1_PREDICTED 20 0.01375383 0.006753247 Col6a1  COL6A1 COL6A1  Homo sapiens collagen, type VI, alpha 1 (COL6A1), mRNA.  
ILMN_1368116 LOC367398   0.017802335 0.015773059 
Rpl17  
RPL17 
RPL17   Homo sapiens ribosomal protein L17 (RPL17), transcript variant 
1, mRNA. 
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ILMN_1359375 LOC499418 20 0.012542188 0.013913949 
Spatc1l  
C21orf56 
C21orf56        Homo sapiens chromosome 21 open reading frame 56 
(C21orf56), transcript variant 1, mRNA. 
 
ILMN_1352529 IER2 19 0.01724612 0.043680416 Ier2  IER2 IER2    Homo sapiens immediate early response 2 (IER2), mRNA.  
ILMN_1354120 LOC691762 
Un|NW_0
47990.1 
0.012963959 0.027361039 
Uncharacteri
sed 
Uncharact
erised 
Uncharacterised 
 
ILMN_1373383 TIPARP_PREDICTED   0.009131615 0.004731935 
 
TIPARP 
TIPARP  Homo sapiens TCDD-inducible poly(ADP-ribose) polymerase 
(TIPARP), transcript variant 1, mRNA. 
 
ILMN_1364683 NECAB2   0.017802335 0.002306649 
Necab2  
NECAB2 
NECAB2  Homo sapiens N-terminal EF-hand calcium binding protein 2 
(NECAB2), mRNA. 
 
ILMN_1360868 RNF40 1 0.021361686 0.015614973 
Rnf40  
RNF40 
RNF40   Homo sapiens ring finger protein 40 (RNF40), transcript variant 
1, mRNA. 
 
ILMN_1373434 RAB28 14 0.01620753 0.043683386 
Rab28  
RAB28 
RAB28   Homo sapiens RAB28, member RAS oncogene family (RAB28), 
transcript variant 1, mRNA. 
 
ILMN_1354535 ZNF386 6 0.014258893 0.029966683 
Zfp386  
ZNF519 
ZNF519     Homo sapiens zinc finger protein 519 (ZNF519), transcript 
variant 1, mRNA. 
ZNF386 is ZNF519 
ILMN_1374435 C1GALT1C1                 X 0.024523282 0.030423928 
C1galt1c1  
C1GALT1C
1 
C1GALT1C1       Homo sapiens C1GALT1-specific chaperone 1 
(C1GALT1C1), transcript variant 1, mRNA. 
 
ILMN_1362029 LOC502490   0.04383255 0.022875929 
Uncharacteri
sed 
Uncharact
erised 
Uncharacterised 
 
ILMN_1351127 PLCL1 9 0.019282511 0.020445748 Plcl1  PLCL1 PLCL1   Homo sapiens phospholipase C-like 1 (PLCL1), mRNA.  
ILMN_1361932 MLL5 4 0.037223421 0.029966683 
Mll5  
MLL5 
MLL5    Homo sapiens myeloid/lymphoid or mixed-lineage leukemia 5 
(trithorax homolog, Drosophila) (MLL5), transcript variant 1, mRNA. 
 
ILMN_1369005 EGR1 18 0.035286665 0.010340909 Egr1  EGR1 EGR1    Homo sapiens early growth response 1 (EGR1), mRNA.  
ILMN_1360758 RGD1308626 15 0.044931617 0.043680416 
Slain1  
SLAIN1 
SLAIN1  Homo sapiens SLAIN motif family, member 1 (SLAIN1), 
transcript variant 1, mRNA. 
similar to SLAIN motif-
containing protein 1 
ILMN_1359043 EGR4 4 0.030741362 0.027467899 Egr4  EGR4 EGR4    Homo sapiens early growth response 4 (EGR4), mRNA.  
ILMN_1368493 RGD1562629_PREDICTED   0.038248485 0.034655248 
 
NBEA 
NBEA    Homo sapiens neurobeachin (NBEA), transcript variant 1, 
mRNA. 
similar to neurobeachin 
ILMN_1349772 FTCD 20 0.039682259 0.009592184 
Ftcd  
FTCD 
FTCD    Homo sapiens formiminotransferase cyclodeaminase (FTCD), 
transcript variant A, mRNA. 
 
ILMN_1361370 RYBP_PREDICTED 4 0.017995019 0.023480201  RYBP RYBP    Homo sapiens RING1 and YY1 binding protein (RYBP), mRNA.  
ILMN_1373798 PLCB1 3 0.024981672 0.020053129 
Plcb1  
PLCB1 
PLCB1   Homo sapiens phospholipase C, beta 1 (phosphoinositide-
specific) (PLCB1), transcript variant 1, mRNA. 
 
ILMN_1372236 ZFP36L1 6 0.038386514 0.040504587 
Zfp36l1  
ZFP36L1 
ZFP36L1 Homo sapiens zinc finger protein 36, C3H type-like 1 
(ZFP36L1), transcript variant 1, mRNA. 
 
ILMN_1349546 MDGA2 6 0.047363636 0.017687075 
Mdga2  
MDGA2 
MDGA2   Homo sapiens MAM domain containing 
glycosylphosphatidylinositol anchor 2 (MDGA2), transcript variant 1, 
mRNA. 
 
ILMN_1353576 GPR149 2 0.04383255 0.024593868 
Gpr149  
GPR149 
GPR149  Homo sapiens G protein-coupled receptor 149 (GPR149), 
mRNA. 
 
ILMN_1354065 LOC686053 
Un|NW_0
47874.1 
0.042841958 0.014360902 
Uncharacteri
sed 
Uncharact
erised 
Uncharacterised 
 
ILMN_1357903 RGD1564171_PREDICTED 2 0.028060375 0.033276328 
Uncharacteri
sed 
Uncharact
erised 
Uncharacterised 
 
ILMN_1361346 RGD1564940_PREDICTED 5 0.031886608 0.033533363 
Uncharacteri
sed 
Uncharact
erised 
Uncharacterised 
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ILMN_1370101 LOC499058   0.046880878 0.022875929 
Uncharacteri
sed 
Uncharact
erised 
Uncharacterised 
 
ILMN_1352135 CEACAM10 1 0.045470541 0.003838384 
Ceacam1  
CEACAM1 
CEACAM1 Homo sapiens carcinoembryonic antigen-related cell 
adhesion molecule 1 (biliary glycoprotein) (CEACAM1), transcript 
variant 4, mRNA. 
CEACAM10 not in RefSeq 
but overlaps with 
CEACAM1 
ILMN_1371662 PPP2R1A 1 0.048310249 0.024218835 
Ppp2r1a  
PPP2R1A 
PPP2R1A Homo sapiens protein phosphatase 2, regulatory subunit A, 
alpha (PPP2R1A), transcript variant 1, mRNA. 
 
ILMN_1363414 LOC365025   0.043867069 0.005140693 
Tuba1b  
TUBA1B As above 
similar to alpha tubulin 
subunit  
ILMN_1370033 LOC498604   0.037413057 0.04984 
Fam129b  
FAM129B 
FAM129B Homo sapiens family with sequence similarity 129, member 
B (FAM129B), transcript variant 1, mRNA. 
similar to B-cell novel 
protein 1 
ILMN_1359027 RGD1563482_PREDICTED 12 0.047780599 0.019192584 
RGD1563482  C12orf65 
C12orf65        Homo sapiens chromosome 12 open reading frame 65 
(C12orf65), transcript variant 1, mRNA. 
similar to hypothetical 
protein FLJ38663 
ILMN_1350094 SDPR 9 0.019282511 0.011280632 Sdpr  SDPR SDPR    Homo sapiens serum deprivation response (SDPR), mRNA.  
ILMN_2039346 HLA-DMA 20 0.017802335 0.00802139 
RT1-DMa  
HLA-DMA 
HLA-DMA Homo sapiens major histocompatibility complex, class II, DM 
alpha (HLA-DMA), mRNA. 
 
ILMN_1349530 CRSP6   0.02584 0.007749775 Med17  MED17 MED17   Homo sapiens mediator complex subunit 17 (MED17), mRNA. CRSP6 = MED17 
ILMN_1369447 RGD1565673_PREDICTED 3 0.015577014 0.043683386 
Ttf1  
TTF1 
TTF1    Homo sapiens transcription termination factor, RNA polymerase I (TTF1), transcript variant 1, 
mRNA. (NKX2-1  Homo sapiens NK2 homeobox 1 (NKX2-1), transcript variant 1, mRNA.) 
ILMN_1355984 TPX2_PREDICTED   0.036723549 0.016383399 
Tpx2  
TPX2 
TPX2    Homo sapiens TPX2, microtubule-associated, homolog 
(Xenopus laevis) (TPX2), mRNA. 
 
ILMN_1350525 XPNPEP1 1 0.011273885 0.036497199 
Xpnpep1  
XPNPEP1 
XPNPEP1 Homo sapiens X-prolyl aminopeptidase (aminopeptidase P) 
1, soluble (XPNPEP1), transcript variant 1, mRNA. 
 
ILMN_1360785 LOC361929 2 0.01569697 0.004775604 
Atp11b  
ATP11B ATP11B  Homo sapiens ATPase, class VI, type 11B (ATP11B), mRNA. 
similar to Potential 
phospholipid-transporting 
ATPase IF  
ILMN_1651182 ANKRD15 1 0.013436679 0.029966683 
Kank1  
KANK1 
KANK1   Homo sapiens KN motif and ankyrin repeat domains 1 
(KANK1), transcript variant 1, mRNA. 
ANKRD15 = KANK1 
ILMN_1360040 NUDT14_PREDICTED   0.007355372 0.01180303 
Nudt14  
NUDT14 
NUDT14  Homo sapiens nudix (nucleoside diphosphate linked moiety 
X)-type motif 14 (NUDT14), mRNA. 
 
ILMN_1354941 COL3A1 9 0.008265852 0.007226814  COL3A1 COL3A1  Homo sapiens collagen, type III, alpha 1 (COL3A1), mRNA.  
ILMN_1374043 ERAF_PREDICTED   0.011252914 0.012742299 
Ahsp  
AHSP 
AHSP    Homo sapiens alpha hemoglobin stabilizing protein (AHSP), 
mRNA. 
 
ILMN_1351156 GNAI1 4 0.038758971 0.006236786 
Gnai1  
GNAI1 
GNAI1   Homo sapiens guanine nucleotide binding protein (G protein), alpha inhibiting activity 
polypeptide 1 (GNAI1), transcript variant 1, mRNA. 
ILMN_1352524 USMG5 1 0.012053872 0.004427391 
Usmg5  
USMG5 
USMG5   Homo sapiens up-regulated during skeletal muscle growth 5 
homolog (mouse) (USMG5), transcript variant 1, mRNA. 
 
ILMN_1374825 LOC294789   0.00608658 0.029223587 
Uncharacteri
sed 
Uncharact
erised 
Uncharacterised 
 
ILMN_1369541 TCF4 18 0.011252914 0.000871212 
Tcf7l2  
TCF7L2 
TCF7L2  Homo sapiens transcription factor 7-like 2 (T-cell specific, HMG-box) (TCF7L2), transcript 
variant 1, mRNA. (TCF4    Homo sapiens transcription factor 4 (TCF4), transcript variant 1, mRNA.) 
ILMN_1357413 LOC360443   0.007355372 0.004427391 
Uncharacteri
sed 
Uncharact
erised 
Uncharacterised 
 
ILMN_1650955 IFI27L   0.028212577 0.01020475 
 
IFI27L2 
IFI27L2            Homo sapiens interferon, alpha-inducible protein 27-like 
2 (IFI27L2), mRNA.  
ILMN_1375028 HTATIP2_PREDICTED   0.023521336 0.036142857 
Htatip2  
HTATIP2 
HTATIP2 Homo sapiens HIV-1 Tat interactive protein 2, 30kDa 
(HTATIP2), transcript variant 1, mRNA. 
 
ILMN_1348843 SLC17A6 1 0.009307057 0.016441558 Slc17a6  SLC17A6 SLC17A6 Homo sapiens solute carrier family 17 (sodium-dependent  
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inorganic phosphate cotransporter), member 6 (SLC17A6), mRNA. 
ILMN_1361722 RBM8_PREDICTED   0.011111111 0.001194296 Rbm8a  RBM8A RBM8A   Homo sapiens RNA binding motif protein 8A (RBM8A), mRNA.  
ILMN_1359627 LOC360919 14 0.002249417 0.01020475 
Afp  
AFP AFP     Homo sapiens alpha-fetoprotein (AFP), mRNA. 
Similar to alpha-
fetoprotein 
ILMN_1358978 RGD1306126 10 0.002584885 0.007217069 
Fam173a  
FAM173A 
FAM173A Homo sapiens family with sequence similarity 173, member 
A (FAM173A), mRNA. 
 
ILMN_1350985 INPP5D 9 0.002191781 0.004427391 
Inpp5d  
INPP5D 
INPP5D  Homo sapiens inositol polyphosphate-5-phosphatase, 145kDa 
(INPP5D), transcript variant 1, mRNA. 
 
ILMN_1367329 PPP1R16A_PREDICTED 7 0.002684492 0.00848199 
Ppp1r16a  
PPP1R16A 
PPP1R16A        Homo sapiens protein phosphatase 1, regulatory 
subunit 16A (PPP1R16A), mRNA. 
 
ILMN_1361915 PDE10A 1 0.001931818 0.008296558 
Pde10a  
PDE10A 
PDE10A  Homo sapiens phosphodiesterase 10A (PDE10A), transcript 
variant 1, mRNA. 
 
ILMN_1365885 MMP14 15 0.002472284 0.043683386 
Mmp14  
MMP14 
MMP14   Homo sapiens matrix metallopeptidase 14 (membrane-
inserted) (MMP14), mRNA. 
 
ILMN_1371064 RPS18 20 0.002236842 0.01076555 Rps18  RPS18 RPS18   Homo sapiens ribosomal protein S18 (RPS18), mRNA.  
ILMN_1372988 FHL2 9 0.002472284 0.007204301 
Fhl2  
FHL2 
FHL2    Homo sapiens four and a half LIM domains 2 (FHL2), transcript 
variant 1, mRNA. 
 
ILMN_1651148 POLR2I_PREDICTED 1 0.0015427 0.001276224 
Polr2i  
POLR2I 
POLR2I  Homo sapiens polymerase (RNA) II (DNA directed) polypeptide 
I, 14.5kDa (POLR2I), mRNA. 
 
ILMN_1350743 PRMT5_PREDICTED 15 0.001505682 0.002164502 
Prmt5  
PRMT5 
PRMT5   Homo sapiens protein arginine methyltransferase 5 (PRMT5), 
transcript variant 1, mRNA. 
 
ILMN_1350481 LOC499790   0.000482375 0.014687924 
Uncharacteri
sed 
Uncharact
erised 
Uncharacterised 
 
ILMN_1352269 RT1-149   0.0015427 0.016747759 
No Human 
Homologue 
No 
Human 
Homologu
e 
No Human Homologue 
 
ILMN_1362726 HMGN3 8 0.001564171 0.011285266 
Hmgn3  
HMGN3 
HMGN3   Homo sapiens high mobility group nucleosomal binding 
domain 3 (HMGN3), transcript variant 1, mRNA. 
 
ILMN_1357163 SYMPK   0.001251863 0.000868687 Sympk  SYMPK SYMPK   Homo sapiens symplekin (SYMPK), mRNA.  
ILMN_1357432 CYP11B1 7 0.000641711 0.003168831 
Cyp11b1  
CYP11B1 
CYP11B1 Homo sapiens cytochrome P450, family 11, subfamily B, polypeptide 1 (CYP11B1), nuclear 
gene encoding mitochondrial protein, transcript variant 1, mRNA. 
ILMN_1359619 LYZL4_PREDICTED 8 0.001564171 0.049642205 Lyzl4  LYZL4 LYZL4   Homo sapiens lysozyme-like 4 (LYZL4), mRNA.  
ILMN_1360418 RGD1302996 20 0.000714286 0.001320755 
RGD1302996  C6orf136 
C6orf136                   Homo sapiens chromosome 6 open reading frame 
136 (C6orf136), transcript variant 3, mRNA. 
uncharacterized protein 
C6orf136 homolog 
ILMN_1649821 HAGHL   0.00040619 0.001603306 
 
HAGHL 
HAGHL   Homo sapiens hydroxyacylglutathione hydrolase-like 
(HAGHL), transcript variant 2, mRNA. 
 
ILMN_1349624 KIF5C_PREDICTED   0.002223587 0.002306649 Kif5c  KIF5C KIF5C   Homo sapiens kinesin family member 5C (KIF5C), mRNA.  
ILMN_1358541 IGFBP6 7 0.000117302 0.002201705 
Igfbp6  
IGFBP6 
IGFBP6  Homo sapiens insulin-like growth factor binding protein 6 
(IGFBP6), mRNA. 
 
ILMN_1363262 CSNK2A1   0.000395257 0.000187166 
Csnk2a1  
CSNK2A1 
CSNK2A1 Homo sapiens casein kinase 2, alpha 1 polypeptide 
(CSNK2A1), transcript variant 1, mRNA. 
 
ILMN_1359301 IGF2   0.000181818 0.011375291 
Igf2  
IGF2 
IGF2    Homo sapiens insulin-like growth factor 2 (somatomedin A) 
(IGF2), transcript variant 1, mRNA. 
 
ILMN_1358234 RGD1562351_PREDICTED   0.000142045 0.000233766 
Uncharacteri
sed 
Uncharact
erised 
Uncharacterised 
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**SHRSP versus WKY differential gene expression at five weeks of age.    *** Human equivalent of SHRSP differentially expressed genes  
              
ILMN_1364214 LOC497864   0.000117302 0.000170455 
Uncharacteri
sed 
Uncharact
erised 
Uncharacterised 
 
ILMN_1351068 RGD1309829_PREDICTED   7.27E-05 9.74E-05 
Ndufaf5  
NDUFAF5 
NDUFAF5     Homo sapiens NADH dehydrogenase (ubiquinone) complex I, assembly factor 5 
(NDUFAF5), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA. 
ILMN_1368752 LOC499378   7.27E-05 9.74E-05 Uncharacteri
sed 
Uncharact
erised 
Uncharacterised 
similar to oocyte-testis 
gene 1 (I can't find a record 
of this gene) 
ILMN_1351487 RT1-A1 20 0 9.74E-05 RT1-CE7  HLA-B As above RT1-A1 is  HLA-B 
ILMN_1353260 PXMP4 3 0 4.33E-05 
Pxmp4  
PXMP4 
PXMP4   Homo sapiens peroxisomal membrane protein 4, 24kDa 
(PXMP4), transcript variant 1, mRNA. 
 
ILMN_1353156 COLQ   0 9.74E-05 
Colq  
COLQ 
COLQ    Homo sapiens collagen-like tail subunit (single strand of homotrimer) of asymmetric 
acetylcholinesterase (COLQ), transcript variant I, mRNA. 
ILMN_1651096 RGD1560364_PREDICTED   0 9.74E-05 
 
VPS13C 
VPS13C  Homo sapiens vacuolar protein sorting 13 homolog C (S. 
cerevisiae) (VPS13C), transcript variant 1A, mRNA. 
 
ILMN_2038792 ALB 14 0 0.000871212 Alb  ALB ALB     Homo sapiens albumin (ALB), mRNA.  
ILMN_1650062 RGD1563903_PREDICTED   0 0 
 
Uncharact
erised 
Uncharacterised 
 
ILMN_1370031 LOC362068   0 0 
Gpr98  
GPR98 
GPR98   Homo sapiens G protein-coupled receptor 98 (GPR98), 
transcript variant 1, mRNA. 
 
ILMN_1371684 LOC499103   0 0 
 
Uncharact
erised 
Uncharacterised 
 
ILMN_1358480 LOC365566   0 0 
 
UBE2SP2 
ZNF286B      Homo sapiens zinc finger protein 286B 
similar to Ubiquitin-
conjugating enzyme E2S 
ILMN_1376663 LOC287167 10 0 0 Hba1  HBA1 HBA1    Homo sapiens hemoglobin, alpha 1 (HBA1), mRNA. HBA2 = HBA1 
ILMN_1349205 RGD1562905_PREDICTED 1 0 0 
Rpl17  RPL17 
As above 
similar to 60S ribosomal 
protein L17 (L23) 
(predicted) 
ILMN_1359180 MRPL18_PREDICTED 1 0 0 
Mrpl18  
MRPL18 
MRPL18  Homo sapiens mitochondrial ribosomal protein L18 
(MRPL18), nuclear gene encoding mitochondrial protein, mRNA.  
 
11 
Table III All candidate SHRSP gene-based results from LBC1936 and CHARGE with WMH variables. Chr is chromosome. nSNPs is the 
number of SNPs in the gene (+/- 50kb). Please note that the gene boundaries are overlapping as SNPs can be allocated to multiple genes, so the 
same SNP could be driving the signal in different genes. The results are ordered by significance. 
    
Discovery:  
LBC1936 
Replication: 
CHARGE 
    Genotyped SNPs Imputed SNPs Imputed SNPs 
     
WMH 
Volume 
Fazekas 
Score  
WMH 
Volume 
Fazekas 
Score  
WMH 
Volume 
Chr Gene 
Start 
Position 
Stop 
Position nSNPs Pvalue Pvalue nSNPs Pvalue Pvalue nSNPs Pvalue 
4 AFP 74,520,796 74,540,356 13 0.0021 0.0009 77 0.0037 0.0037 67 0.83 
4 ALB 74,488,869 74,505,834 11 0.0027 0.0017 61 0.0063 0.0068 53 0.75 
7 GNAI1 79,602,075 79,686,661 42 0.034 0.033 181 0.014 0.015 166 0.79 
1 RBM8A 144,218,994 144,222,801 13 0.038 0.057 26 0.029 0.024 21 0.54 
2 INPP5D 233,633,279 233,781,288 69 0.041 0.78 198 0.044 0.868 162 0.98 
10 XPNPEP1 111,614,513 111,673,192 18 0.042 0.14 130 0.145 0.23 120 0.000101 
9 NR4A3 101,623,957 101,668,994 13 0.045 0.16 62 0.106 0.245 56 0.48 
13 FARP1 97,593,434 97,900,024 154 0.049 0.25 550 0.18 0.507 468 0.025 
18 RPL17 45,268,853 45,272,904 16 0.058 0.13 79 0.076 0.218 74 0.28 
6 MRPL18 160,131,481 160,139,451 24 0.059 0.039 89 0.16 0.048 76 0.24 
4 RAB28 12,978,479 13,095,054 11 0.076 0.49 84 0.264 0.61 40 0.18 
8 CYP11B1 143,950,774 143,958,238 30 0.080 0.49 103 0.15 0.613 87 0.13 
2 SDPR 192,407,280 192,420,226 15 0.081 0.10 68 0.24 0.314 55 0.25 
1 SIPA1L2 230,600,334 230,717,866 80 0.087 0.00934 340 0.20 0.018 285 0.87 
6 PDE10A 165,664,524 165,995,575 159 0.094 0.065 594 0.15 0.168 534 0.57 
13 SLAIN1 77,170,470 77,236,378 26 0.10 0.30 137 0.19 0.341 124 0.51 
2 KIF5C 149,349,288 149,591,519 31 0.10 0.66 148 0.14 0.711 128 0.35 
12 IGFBP6 51,777,702 51,782,395 16 0.13 0.08 67 0.17 0.065 60 0.24 
21 COL6A1 46,226,090 46,249,391 27 0.14 0.28 96 0.080 0.20 93 0.66 
2 FHL2 105,343,714 105,421,392 47 0.15 0.56 179 0.11 0.55 167 0.37 
5 SLC1A3 36,642,213 36,724,193 71 0.15 0.45 211 0.27 0.74 186 0.16 
19 RPS16 44,615,686 44,618,458 20 0.16 0.43 60 0.38 0.69 53 0.61 
12 
2 SCN3A 165,652,275 165,768,823 33 0.17 0.83 135 0.11 0.88 124 0.90 
21 C21orf56 46,405,497 46,428,729 38 0.17 0.12 113 0.070 0.043 100 0.36 
16 RNF40 30,681,130 30,694,039 5 0.17 0.58 11 0.21 0.66 11 0.30 
14 FOS 74,815,283 74,818,665 28 0.17 0.37 78 0.58 0.46 56 0.14 
1 BTG2 201,541,286 201,545,352 19 0.18 0.33 98 0.37 0.55 81 0.93 
20 TM9SF4 30,160,969 30,218,722 16 0.20 0.29 86 0.28 0.17 72 0.44 
9 TTF1 134,240,757 134,272,042 37 0.20 0.23 96 0.61 0.40 86 0.42 
1 CYR61 85,819,047 85,821,978 32 0.20 0.24 107 0.28 0.45 84 0.73 
14 NUDT14 104,710,320 104,718,685 19 0.21 0.088 67 0.28 0.10 56 0.039 
19 RPS9 59,396,537 59,403,327 22 0.21 0.77 115 0.011 0.49 61 0.051 
2 RPL31 100,985,122 101,002,587 28 0.21 0.27 129 0.066 0.16 124 0.11 
12 DUSP6 88,265,967 88,270,427 20 0.22 0.16 86 0.35 0.18 75 0.12 
11 SLC17A6 22,316,242 22,357,619 39 0.23 0.78 159 0.12 0.86 150 0.90 
3 TIPARP 157,875,072 157,907,228 24 0.29 0.92 144 0.30 0.47 81 0.69 
15 VPS13C 59,931,881 60,139,939 56 0.30 0.76 341 0.57 0.80 290 0.72 
6 CTGF 132,311,009 132,314,211 33 0.30 0.16 138 0.78 0.48 129 0.14 
6 HLA-DMA 33,024,372 33,028,831 95 0.31 0.54 176 0.41 0.73 151 0.94 
6 C6orf136 30,722,779 30,728,961 38 0.32 0.92 61 0.39 0.94 27 0.56 
4 GUCY1A3 156,807,327 156,871,226 55 0.33 0.49 147 0.51 0.49 114 0.29 
16 ZNF597 3,426,110 3,433,491 19 0.33 0.70 83 0.20 0.62 80 0.45 
16 HBA1 166,678 167,520 16 0.34 0.26 27 0.37 0.34 23 0.24 
5 EGR1 137,829,079 137,832,903 16 0.34 0.91 42 0.62 0.94 33 0.031 
19 ZNF575 48,729,168 48,732,124 18 0.34 0.080 69 0.232 0.089 62 0.25 
17 DHX40 54,997,667 55,040,484 10 0.36 0.19 61 0.55 0.27 59 0.17 
17 PER1 7,984,512 7,996,478 27 0.38 0.49 77 0.55 0.57 64 0.14 
20 C20orf7 13,713,681 13,745,874 28 0.39 0.11 147 0.83 0.17 130 0.024 
5 ZCCHC9 80,633,177 80,644,872 22 0.39 0.14 81 0.57 0.30 74 0.92 
9 KANK1 494,702 736,103 169 0.40 0.19 613 0.52 0.43 580 0.069 
18 MEX3C 46,954,917 46,977,688 15 0.41 0.22 78 0.38 0.31 76 0.51 
10 TCF7L2 114,699,998 114,916,060 49 0.42 0.73 166 0.79 0.87 145 0.12 
20 PXMP4 31,754,210 31,771,797 9 0.43 0.44 34 0.40 0.59 32 0.38 
12 C12orf65 122,283,415 122,308,459 4 0.43 0.73 64 0.62 0.39 51 0.11 
13 
1 PLA2G2A 20,174,517 20,179,496 26 0.44 0.46 75 0.29 0.54 68 0.31 
16 NECAB2 82,559,737 82,593,880 54 0.44 0.48 259 0.71 0.79 215 0.30 
19 FKBP8 18,503,567 18,515,383 9 0.44 0.74 49 0.37 0.87 44 0.57 
19 ZNF582 61,586,459 61,596,701 22 0.46 0.22 82 0.27 0.27 71 0.22 
3 RYBP 72,506,438 72,578,464 29 0.46 0.52 128 0.49 0.50 122 0.57 
14 STRN3 30,432,755 30,565,358 39 0.48 0.44 166 0.44 0.46 131 0.12 
19 SYMPK 51,010,539 51,058,388 23 0.48 0.64 79 0.36 0.36 78 0.24 
14 PRMT5 22,459,572 22,468,501 17 0.51 0.99 68 0.58 1.00 61 0.46 
15 ADPGK 70,830,760 70,863,179 19 0.51 0.76 73 0.49 0.71 73 0.089 
16 FAM173A 711,158 712,591 16 0.51 0.68 39 0.24 0.70 32 0.91 
21 FTCD 46,380,603 46,399,909 31 0.52 0.33 104 0.32 0.19 87 0.47 
6 HLA-B 31,429,627 31,432,968 84 0.52 0.67 383 0.45 0.53 353 0.77 
12 TUBA1B 47,807,832 47,811,571 3 0.52 0.71 30 0.16 0.47 29 0.21 
19 POLR2I 41,296,450 41,298,046 12 0.53 0.80 42 0.22 0.87 32 0.47 
6 HMGN3 79,967,680 80,001,174 29 0.54 0.44 124 0.55 0.35 84 0.65 
3 GPR149 155,538,154 155,630,198 32 0.54 0.50 167 0.68 0.59 156 0.23 
8 TCEB1 75,021,187 75,046,900 24 0.54 0.79 91 0.50 0.89 82 0.81 
16 HAGHL 716,958 719,716 15 0.55 0.45 42 0.31 0.63 31 0.90 
2 COL3A1 189,547,343 189,585,717 27 0.56 0.18 143 0.62 0.17 124 0.83 
2 EGR4 73,371,564 73,374,181 8 0.57 0.43 43 0.72 0.22 40 0.39 
16 ERAF 31,446,703 31,447,625 11 0.57 0.75 48 0.31 0.53 47 0.71 
14 NFKBIA 34,940,466 34,943,711 23 0.57 0.65 95 0.71 0.76 90 0.65 
19 ZNF583 61,607,529 61,628,212 28 0.58 0.41 88 0.32 0.42 78 0.33 
6 SGK1 134,532,076 134,537,727 21 0.59 0.79 78 0.78 0.87 67 0.62 
9 FAM129B 129,307,438 129,381,089 31 0.59 0.37 119 0.92 0.42 113 1.00 
2 PLCL1 198,377,777 198,721,365 49 0.60 0.99 270 0.86 0.99 256 0.93 
11 MED17 93,157,052 93,186,144 15 0.60 0.46 65 0.86 0.60 62 0.0095 
5 FAM151B 79,819,555 79,873,962 17 0.60 0.51 96 0.83 0.72 74 0.26 
20 TPX2 29,790,564 29,853,264 16 0.62 0.35 112 0.60 0.37 108 0.37 
6 RPS18 33,347,829 33,352,259 14 0.64 0.66 63 0.81 0.72 58 0.37 
19 CEACAM1 47,703,297 47,724,479 4 0.64 0.55 29 0.82 0.70 27 0.92 
3 COLQ 15,466,643 15,538,262 37 0.65 0.38 145 0.88 0.41 135 0.47 
14 
10 RAB18 27,833,254 27,869,105 22 0.66 0.70 103 0.79 0.74 96 0.80 
19 IER2 13,122,281 13,126,718 15 0.67 0.71 33 0.45 0.66 21 0.19 
3 LYZL4 42,413,578 42,427,069 28 0.68 0.72 138 0.88 0.88 112 0.99 
3 ATP11B 183,993,984 184,122,115 26 0.69 0.21 135 0.89 0.37 134 0.50 
5 DUSP1 172,127,706 172,130,809 34 0.69 0.98 107 0.79 0.98 90 0.29 
11 HTATIP2 20,341,806 20,361,905 24 0.69 0.44 118 0.86 0.53 112 0.38 
2 RNF149 101,258,984 101,291,584 16 0.72 0.41 88 0.77 0.47 85 0.30 
19 FAM32A 16,157,234 16,163,857 16 0.72 0.72 80 0.68 0.94 77 0.17 
19 ZNF317 9,112,085 9,135,089 30 0.72 0.96 74 0.72 0.95 71 0.11 
1 GALNT2 228,269,650 228,484,569 99 0.74 0.18 328 0.89 0.45 284 0.31 
19 ZNF566 41,630,421 41,672,177 16 0.76 0.52 59 0.91 0.82 59 0.26 
14 MDGA2 46,378,577 47,213,738 164 0.76 0.63 1036 0.75 0.73 967 0.89 
19 ZNF45 49,108,620 49,121,398 16 0.76 0.88 90 0.67 0.79 81 0.061 
1 RPL22 6,167,666 6,182,266 19 0.78 0.89 44 0.87 0.98 30 0.46 
1 PTGS2 184,907,591 184,916,179 16 0.79 0.44 75 0.99 0.73 68 0.98 
7 MLL5 104,441,872 104,541,768 21 0.79 0.39 98 0.61 0.66 97 0.94 
10 USMG5 105,138,803 105,146,213 10 0.79 0.88 31 0.92 0.96 28 0.000142 
14 MMP14 22,375,632 22,386,643 40 0.79 0.90 99 0.87 0.97 75 0.046 
19 PPP2R1A 57,385,045 57,421,483 47 0.80 0.66 141 0.94 0.84 132 0.41 
6 OOEP 74,135,000 74,136,236 9 0.80 0.93 65 0.76 0.92 55 0.87 
8 PPP1R16A 145,692,916 145,698,312 6 0.81 0.11 24 0.78 0.25 20 0.27 
8 ARC 143,689,411 143,692,835 17 0.81 0.94 81 0.22 0.98 78 0.033 
5 GPR98 89,890,372 90,495,789 142 0.82 0.75 657 0.91 0.88 591 0.74 
9 ZNF189 103,200,983 103,212,763 25 0.82 0.30 135 0.72 0.28 128 0.98 
10 POLL 103,328,628 103,337,963 12 0.83 0.90 79 0.90 0.76 73 0.69 
10 EGR2 64,241,762 64,246,133 21 0.84 0.93 100 0.88 0.95 97 0.84 
2 NAB1 191,222,092 191,265,737 17 0.85 1.00 88 0.87 1.00 86 0.12 
14 ZFP36L1 68,324,127 68,329,538 31 0.86 0.47 87 0.76 0.41 84 0.20 
2 PER2 238,817,417 238,861,946 18 0.87 0.96 92 0.20 0.66 70 0.37 
14 FAM14A 93,663,870 93,665,710 34 0.87 0.98 96 0.98 1.00 89 0.35 
18 ZNF519 14,094,723 14,122,429 13 0.88 0.75 49 0.87 0.83 41 0.86 
20 CSNK2A1 411,337 472,482 34 0.90 0.53 115 0.94 0.29 100 0.41 
15 
4 GPM6A 176,791,081 177,160,642 95 0.90 0.95 383 0.94 0.98 315 0.053 
13 NBEA 34,414,455 35,144,873 114 0.93 0.72 621 0.99 0.82 571 0.32 
11 IGF2 2,106,922 2,127,409 21 0.94 0.64 83 0.92 0.64 67 0.32 
1 RGS2 191,044,793 191,048,026 11 0.94 0.82 84 0.88 0.63 74 0.77 
1 BAI2 31,965,304 32,002,235 17 0.95 0.65 61 0.91 0.61 54 0.12 
20 PLCB1 8,061,295 8,813,547 290 0.95 0.84 1123 0.94 0.94 1027 0.61 
19 ZNF461 41,820,122 41,849,579 9 0.98 0.55 54 0.90 0.61 52 0.016 
19 JUNB 12,763,309 12,765,125 5 0.99 0.48 29 1.00 0.58 13 0.49 
16 
Table IV Top hits from genome wide association study with WMH variables in LBC1936 (P 
< 1x10-5). 
SNP Chromosome Position Nearest Gene Risk Allele 
Allele 
Frequency Beta P 
WMH        
rs7312545 12 104,877,937 NUAK1 A 0.48 0.1775 4.70x10-6 
rs1908311 1 164,698,889 FMO9P T 0.34 0.1761 6.27 x10-6 
rs1778193 1 94,886,005 SLC44A3/F3 T 0.10 -0.1733 7.50 x10
-6
 
rs1344567 12 104,869,369 NUAK1 T 0.49 0.1735 7.71 x10-6 
rs10439220 2 235,653,271 SH3BP4 C 0.27 0.1735 8.05 x10-6 
Fazekas 
score 
       
rs1156440 4 106,244,538 TET2 A 0.26 0.1931 1.45 x10-6 
rs764275 4 106,236,076 TET2 G 0.26 0.1858 3.67 x10-6 
rs1991979 4 147,368,197 LSM6/SLC10A7 C 0.37 0.1794 8.27 x10-6 
rs9905906 17 7,626,473 DNAH2 T 0.35 0.1778 8.58 x10-6 
rs1923416 6 89,348,510 RNGTT C 0.11 0.1771 8.92 x10-6 
rs13250792 8 16,784,710 FGF20 G 0.27 0.1773 9.50 x10-6 
rs6561615 13 50,595,795 GUGY1B2 A 0.13 0.1773 9.87 x10-6 
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Table V Top gene-based results for the LBC1936 WMH variables analysed in Vegas (P<0.001). Chr is chromosome. nSNPs is the number of 
SNPs in the gene (+/- 50kb). Please note that the gene boundaries are overlapping as SNPs can be allocated to multiple genes, so the same SNP 
could be driving the signal in different genes. The results are ordered by significance. 
WMH Fazekas Score 
Chr Gene nSNPs Start Stop P Chr Gene nSNPs Start Stop P 
17 FBF1 17 71,418,212 71,448,714 8.00x10-6 17 TRIM65 10 71,396,635 71,404,649 5.7x10-5 
17 MRPL38 10 71,406,318 71,413,069 1.20 x10-5 17 FBF1 17 71,418,212 71,448,714 6.10x10-5 
17 TRIM65 10 71,396,635 71,404,649 1.80 x10-5 19 HDGF2 21 4,423,254 4,453,222 6.70x10-5 
17 TRIM47 10 71,381,839 71,386,251 1.90 x10-5 17 MRPL38 10 71,406,318 71,413,069 6.70 x10-5 
17 WBP2 11 71,353,374 71,363,096 2.20 x10-5 17 TRIM47 10 71,381,839 71,386,251 7.40 x10-5 
17 UNC13D 13 71,334,901 71,352,393 3.50 x10-5 19 UBXD1 16 4,396,260 4,408,790 8.30 x10-5 
17 ACOX1 26 71,449,186 71,487,039 5.00 x10-5 4 LSM6 17 147,316,284 147,330,663 1.00 x10-5 
15 SLC12A1 27 46,285,789 46,383,568 7.10 x10-5 19 LRG1 22 4,488,226 4,491,036 0.00010 
15 DUT 20 46,410,912 46,422,862 8.40 x10-5 1 MRPL24 17 154,973,717 154,977,547 0.00011 
17 UNK 21 71,292,275 71,333,481 0.00012 1 HDGF 17 154,978,522 154,988,864 0.00012 
1 CD55 14 205,561,439 205,600,934 0.00022 17 WBP2 11 71,353,374 71,363,096 0.00014 
4 LSM6 17 147,316,284 147,330,663 0.00024 1 ISG20L2 19 154,959,036 154,964,329 0.00016 
9 ODF2 8 130,258,252 130,303,060 0.00035 1 C1orf66 19 154,964,901 154,973,365 0.00016 
1 MRPL24 17 154,973,717 154,977,547 0.00037 17 UNC13D 13 71,334,901 71,352,393 0.00022 
7 FLJ21075 48 47,801,413 47,825,969 0.00047 19 LSDP5 24 4,473,543 4,486,208 0.00025 
2 ANKRD44 61 197,567,494 197,771,007 0.00054 19 KIAA1881 23 4,453,191 4,468,716 0.00031 
17 H3F3B 17 71,284,109 71,287,455 0.00055 16 SSTR5 30 1,068,869 1,069,964 0.00031 
1 C1orf66 19 154,964,901 154,973,365 0.00059 17 UNK 21 71,292,275 71,333,481 0.00035 
17 TMEM106A 2 38,719,419 38,727,115 0.00059 19 MAP1S 25 17,691,302 17,706,324 0.00038 
1 ISG20L2 19 154,959,036 154,964,329 0.00059 13 PARP4 37 23,893,068 23,984,948 0.00047 
17 NBR1 3 38,576,023 38,719,233 0.00061 20 NKX2-2 10 21,439,651 21,442,664 0.00049 
1 HDGF 17 154,978,522 154,988,864 0.00066 19 SEMA6B 24 4,493,599 4,509,503 0.00068 
17 LOC100134934 23 71,486,895 71,508,262 0.00077 15 TLE3 34 68,127,596 68,177,310 0.00081 
9 CERCAM 8 130,222,579 130,239,451 0.00090 16 C1QTNF8 28 1,078,226 1,086,245 0.00089 
      4 AFP 13 74,520,796 74,540,356 0.00090 
      17 ACOX1 26 71,449,186 71,487,039 0.00094 
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Figure I Genome-wide association study results of WMH volume (a) and Fazekas score (b) 
using genotyped data on 542,050 SNPs in LBC1936. QQ and Manhattan plots are shown.  
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